Today: 20 March 2026
Subscribe
Browse Category

NASDAQ:GRAL 3 October 2025 - 27 February 2026

GRAIL Inc. Stock Rises on Samsung Partnership and Cancer-Test News

GRAIL Stock Rockets on Samsung Mega-Deal and Cancer Test Breakthrough

GRAIL shares surged 14% to a record $85.35 on Oct. 16 after Samsung agreed to invest $110 million and partner on cancer test rollout in Asia. New trial data showed Galleri’s blood test boosted early cancer detection seven-fold in a 25,000-patient study. GRAIL secured $325 million in fresh funding, extending its cash runway into 2030. Analysts remain cautious, with a consensus Hold rating and a $57 price target.
20 October 2025
···
GRAIL (GRAL) Stock Skyrockets on Samsung’s $110M Bet and Cancer-Screening Breakthrough

GRAIL (GRAL) Stock Skyrockets on Samsung’s $110M Bet and Cancer-Screening Breakthrough

GRAIL shares surged 13–14% to a record $85.35 on Oct. 16 after announcing a $110 million equity deal with Samsung and plans to bring its Galleri cancer test to Asia. New trial data at ESMO showed Galleri doubled early cancer detection versus routine screening. Despite gains, most analysts rate GRAL a “Hold” with an average target below current prices. Q2 revenue rose 11% to $35.5M; net loss narrowed to $114M.
18 October 2025
···
Biotech Breakthrough: GRAIL (GRAL) Stock Surges on New Cancer-Detection Data

GRAIL (GRAL) Rockets to Record High on Samsung Mega-Deal and Cancer Test Breakthrough

GRAL stock surged 14% to a record $86 after Samsung agreed to invest $110 million and help launch GRAIL’s Galleri cancer blood test in Asia. New trial data showed the test doubled early cancer detection rates. GRAIL shares are up over 300% this year, valuing the company at $2.7 billion. Most analysts rate the stock “Hold,” with average targets well below current prices.
17 October 2025
····
GRAIL Inc. Stock Rises on Samsung Partnership and Cancer-Test News

GRAIL Inc. Stock Rises on Samsung Partnership and Cancer-Test News

GRAIL shares jumped 13.6% to close at $85.82 on Oct. 16 after announcing a $110 million equity investment and distribution deal with Samsung C&T and Samsung Electronics. Samsung C&T will exclusively distribute GRAIL’s Galleri cancer test in South Korea, with possible expansion to Japan and Singapore. GRAL’s market cap rose to about $2.7 billion. Most analysts maintain a Hold rating despite the stock’s 321% year-to-date gain.
16 October 2025
···
Biotech Breakthrough: GRAIL (GRAL) Stock Surges on New Cancer-Detection Data

Biotech Breakthrough: GRAIL (GRAL) Stock Surges on New Cancer-Detection Data

GRAL shares surged to $69.14 intraday on Oct 3, up nearly 6.8% and about 248% year-to-date. Market cap reached $2.3–2.5 billion, a 472% jump since mid-2024, despite ongoing losses and negative EPS. Wall Street consensus remains “Hold” with a $31.50 average price target, far below current levels. Investors await new PATHFINDER 2 trial data at ESMO Congress later this month.
3 October 2025
···

Stock Market Today

  • European Stocks Rise as Oil Prices Drop and Rate Hike Bets Grow
    March 20, 2026, 5:11 AM EDT. European stocks rebounded on Friday, led by banking and construction sectors, as oil prices eased from recent highs above $119 a barrel. The decline followed U.S. signals about possibly lifting sanctions on Iranian crude to reduce energy costs. Central banks across Europe, including the European Central Bank (ECB) and Bank of England (BoE), held interest rates steady amid uncertainty from the U.S.-Iran conflict but traders increased bets on further rate hikes later this year. The ECB highlighted inflation risks tied to the war, while the BoE's unanimous hold hinted at readiness to act. Meanwhile, Unilever disclosed talks to sell part of its foods business to McCormick & Company, adding corporate activity amid market shifts.
Go toTop